Nautilus Biotechnology Reports $59M Net Loss for Fiscal Year 2025, Plans Phased Commercialization of Proteomics Platform

Nautilus Biotechnology, Inc. has reported a net loss of $59.0 million for the fiscal year ending December 31, 2025, a decrease from the $70.8 million loss recorded in the previous year. The company, which has not yet generated any revenue from product sales, continues to invest heavily in the development of its proteomics platform, the Nautilus VoyagerTM, which is designed to provide comprehensive protein analysis. As of the end of 2025, Nautilus had an accumulated deficit of $332.0 million, reflecting its ongoing investment in research and development activities.

Operating expenses for the year totaled $66.8 million, down 18% from $81.5 million in 2024. This reduction was primarily driven by a 19% decrease in research and development expenses, which fell to $41.1 million, attributed to operational efficiencies and a reduction in workforce implemented earlier in 2025. General and administrative expenses also decreased by 17% to $25.7 million, largely due to lower stock-based compensation and professional service costs. Despite these reductions, the company anticipates continued significant losses as it progresses toward commercialization.

Nautilus is in the early stages of launching its Nautilus Voyager platform, with plans to initiate a phased commercialization strategy. The company has launched an Early Access Program, allowing select customers to utilize the platform for targeted proteoform analysis, specifically focusing on the Tau protein associated with neurodegenerative diseases. The full commercial launch is expected in late 2026, with instrument installations beginning in early 2027. The company aims to expand its offerings to include broadscale proteomics capabilities by mid-2027.

As of December 31, 2025, Nautilus had cash, cash equivalents, and short-term investments totaling $156.1 million, which the company believes will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for additional capital to support ongoing research and development, as well as to establish sales and marketing capabilities. The financial outlook remains uncertain, with the potential for future funding challenges due to market conditions and the company's reliance on research and development spending by its customers.

In summary, Nautilus Biotechnology is focused on advancing its innovative proteomics platform while managing significant financial losses. The company is strategically positioning itself for future growth through targeted collaborations and a phased commercialization approach, although it faces ongoing challenges related to funding and market acceptance of its technology.